S9921PAT Data Dictionary											
olumn ımber	Variable	Var. Label	Type	Units	Value	Value Definition	Additional Notes				
	ALTPATID	SWOG Patient ID	Char	Units	value	Definition	Notes				
	ALITATIO	SWOOT Allent ID	Cital		N	No					
2	POP	Analysis Population	Char		Y	Yes					
	1 01	7 transitor opulation	Onai		N	No					
3	CLINTOX	Assessable for Adverse Events	Char		Y	Yes					
	02	Acceptable for Adverse Evente	- Ona		N	No					
4	NATIVE	Indicator Native American	Char		Υ	Yes					
					N	No					
5	ASIAN	Indicator for Asian	Char		Υ	Yes					
					N	No					
6	BLACK	Indicator for Black	Char		Υ	Yes					
					N	No					
7	PACIFIC	Indicator for Pacific Islander	Char		Υ	Yes					
					N	No					
8	WHITE	Indicator for White	Char		Υ	Yes					
					N	No					
9	UNKRACE	Indicator for Unknown Race	Char		Υ	Yes					
	l				N	No					
	HISPANIC	Indicator for Hispanic	Char	.,	Υ	Yes					
11	AGEYRS	Age at Randomization	Num	Years							
					1	Androgen Deprivation Therapy Only					
12	TRNO	Protocol Treatment ID	Num		2	Androgen Deprivation Therapy + mitoxantrone + prednisone					
	T)(1 A D E 1		0.		AD only	Androgen Deprivation Therapy Only					
	TXLABEL	Treatment Arm Label	Char	/	MP + AD	Androgen Deprivation Therapy + mitoxantrone + prednisone					
14	PREOP_PSA	Pre-RP PSA level	INUM	ng/mL	4	Orner Confined (T4 T2) Neda Negative Diagona (NO)					
					2	Organ Confined (T1-T2), Node Negative Disease (N0) Non-Organ Confined (T3), Node Negative Disease (N0)					
15	DISEASE	ASE Extent of Disease	Num		3	Node Positive Disease (N1)					
13	DISEASE EXIC	Extent of Disease			1	<= 6					
					2	7					
16	GLGRP	Gleason Score Group	Num		3	<i>t</i>  >=8					
10	GLGIKI	Gleason Score Group	INUITI		1	Gleason Score <=7, Positive Margins OR PSA > 10 ng/mL					
					2	Gleason Score >=8 or pT3b					
17	RISKGRP	Risk Group per JCO pub	Num		3	Node Positive					
	rtiortorti	Trion Group por GGG pub	rtuiii		N	No					
18	HIGHGRADE	High-Grade Disease	Char		Y	Yes					
					N	No					
19	RTINTENT	Intent for adjuvant RT Y/N	Char		Y	Yes					
		,			N	No					
20	ADJRT	Received Adjuvant RT	Char		Υ	Yes					
					N	No					
21	POSMARG	Positive Margins Y/N	Char		Υ	Yes					
					Completed Tx						
					Refused all Treatment		NOTE: Due to data cleaning efforts subsequent to publication,				
					Stopped Early for AE,		data may contain slight discrepancies from that reported in				
					Refused or Other		Figure 1 of the publication				
					Stopped due to Death or		rigule 1 of the publication				
22	ALLOCATION	Consort Category	Char		Progression						
					N	No	NOTE: Due to data cleaning efforts subsequent to publication,				
					N/A	Not Applicable	data may contain slight discrepancies from that reported in				
23	COMPCHEMO	Completed Chemotherapy	Char		Υ	Yes	Figure 1 of the publication				
		,,			N	Not Prostate Cancer Related	NOTE: Due to data cleaning efforts subsequent to publication,				
					U	Unknown	data may contain slight discrepancies from that reported in				
24	PROS_DEATH	Prostate Death?	Char		Y	Prostate Cancer Related	Table 3 of the publication				
	_						NOTE: Due to data cleaning efforts subsequent to publication,				
					0	No Death (Censor)	data may contain slight discrepancies from that reported in				
25	SURIND	Overall Survival Indicator	Num		1	Death	Table 4 of the publication				
20	COMME	S TOTAL GALVIVA HIGIOAGO	140111				NOTE: Due to data cleaning efforts subsequent to publication,				
						If Death: Date of Death - Date of Trial Registration	data may contain slight discrepancies from that reported in				
	I .	Overall Survival Time		Days		If No Death: Date of Last Contact - Date of Trial Registration	Table 4 of the publication				

S9921PAT Data Dictionary											
Column						Value	Additional				
Number	Variable	Var. Label	Type	Units	Value	Definition	Notes				
					0	No Event (Censor)					
27	RECURIND	Recurrence Indicator	Num		1	Recurrence Event					
					0	No Event (Censor)	NOTE: Due to data cleaning efforts subsequent to publication, data may contain slight discrepancies from that reported in				
28	DFSIND	Disease-Free Survival Indicator	Num		1	DFS Event	Table 4 of the publication				
29	DFSTIM	Disease-Free Survival Time	Num	Days		If DFS Event: Minimum of (Date of Death - Date of Trial Registration, Date of Disease Recurrence - Date of Trial Registration)  If No DFS Event: Date of Last Contact - Date of Trial Registration	NOTE: Due to data cleaning efforts subsequent to publication, data may contain slight discrepancies from that reported in Table 4 of the publication				
		Post Treatment Testosterone			0	No Event (Censor)					
30	RECIND	Recovery (>=50 ng/mL) Indicator	Num		1	Testosterone Recovery Event					
31	MIN_REC_MTHS	Minimum Possible Testosterone Recovery Time	Num	Months							
		Maximum Possible Testosterone									
32	MAX_REC_MTHS	Recovery Time	Num	Months							
33	MIN_REC_TESTOS	Testosterone at Minimum Possible Recovery Time	Num	ng/mL							
34	MAX_REC_TESTOS	Testosterone at Maximum Possible Recovery Time	Num	ng/mL							
NOTE: Unless otherwise specified, blank values indicated missing data											